Small-Cap Bioquell plc Surges On Ebola Outbreak

Shares in Bioquell plc (LON: BQE) rise by 13% due to continued fears surrounding Ebola

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

diploma

It’s been a hugely disappointing year for investors in Bioquell (LSE: BQE), with shares in the decontamination unit specialist falling by as much as 40% from the start of the year until the end of September.

However, as a result of continuing fears surrounding a potential outbreak of Ebola in Europe, market sentiment has picked up strongly in recent days. Shares in Bioquell are up 13% on the day (at the time of writing) as investors believe that demand for Bioquell’s products could increase over the short to medium term.

Right Product, Right Time

Indeed, Bioquell’s decontamination units provide hospitals with a simple and relatively straightforward solution for the treatment of diseases such as Ebola. Not only do they provide a means of preventing contamination, they also allow patients to be easily treated and are fairly straightforward to set up. In other words, new hospital wards are not required to accommodate them; they can be erected in existing wards in a relatively short timeframe and are highly effective in preventing contamination.

This could prove to be a perfect solution for the Ebola outbreak because we remain unsure of how severely it could affect the UK and Europe. As a result, the short lead time required to get Bioquell’s key product up and running could prove to be highly appealing to health agencies, thereby providing a boost to Bioquell’s sales in the short run.

Increased Exposure

Of course, the fact that Bioquell is gaining attention not only from investors but from the public, too, is a good thing for the company and for its shareholders. That’s because Bioquell’s decontamination units are also an effective means of partitioning an open ward so as to provide increased privacy for patients and their families. In other words, during a period of austerity, Bioquell’s units could be a means of improving the layout and offering at hospitals without the significant cost and interruption that comes with a building project.

Looking Ahead

With or without an Ebola outbreak in the UK, Bioquell seems to have bright future. For example, the company’s bottom line is expected to grow by 43% next year and, with shares in the company trading on a price to earnings (P/E) ratio of 25, this equates to a price to earnings growth (PEG) ratio of just 0.6. This is highly appealing and shows that Bioquell offers growth at a very reasonable price.

Of course, an Ebola outbreak across the UK and Europe could stimulate demand for Bioquell’s decontamination unit and send profits and its share price even higher. However, the exposure the company is currently gaining from a potential outbreak could be enough to increase demand for its units even if it does not materialise. As such, and with shares offering good value, Bioquell could move higher over the medium term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »